Nanologica AB has engaged two senior scientific advisors within the field of respiratory drug delivery, for the purpose of advancing the NLAB Spiro™ inhalation platform further.
Dr. John Pritchard has more than 40 years of experience from the inhalation industry working in various positions, leading and managing global portfolios of technology projects from discovery to market, at for example GlaxoSmithKline, 3M Health Care Ltd and as Head of Respiratory Project Management at AstraZeneca. His vast experience from the respiratory drug delivery field also includes serving on a Technical Advisory Board for AstraZeneca, advising on their dry powder inhaler developments, and on the Science Advisory Board of Prosonix Ltd. He is currently assisting companies in the respiratory space, including as a Director for 3 SMEs in the UK and USA.
Dr. Gary Pitcairn is a recognized expert in inhaled drug delivery, with extensive device experience (DPI, pMDI and nebulizer) and product development experience, from preclinical through to late phase, including FDA interactions leading to NDA submissions. Dr. Pitcairn is also an experienced senior leader, with a successful track record of leading global multidisciplinary teams, at for example Pfizer, Mylan and most recently AstraZeneca where he has led a group of Global Project Directors accountable for the strategy and delivery of respiratory projects, from Phase II through to launch and on-market support.
” We are very excited having engaged Dr. Pritchard and Dr. Pitcairn as scientific advisors for our inhalation platform. Their vast experience within the field will be invaluable to Nanologica when advancing the platform towards clinical projects”, says Kia Bengtsson, Director Drug Development at Nanologica.
“I am very much looking forward to working with Gary and the Nanologica team on this impressive new approach to drug delivery” says Dr. John Pritchard.
Currently, toxicity studies on the NLAB Spiro™ platform are ongoing. The first read-out from the studies is expected during the second quarter of 2021.
For further information, please contact:
Johanna Johansson, IR Nanologica
Ph: +46 72 211 21 90 or e-mail: email@example.com
About Nanologica AB (publ)
Nanologica was founded in 2004 and is a nanotechnology company developing nanoporous silica particles for applications within life science. Nanologica is world-leading in controlling the shape, size, and type of porosity of silica particles. This knowledge is applied within drug development and chromatography (a separation technique used in drug development and drug production). The company’s mission is to contribute to better and cheaper treatments for patients worldwide through the technology platform NLAB Silica™. Nanologica’s stock (NICA) is listed on Spotlight Stock Market. For further information, please visit www.nanologica.com.
About NLAB Spiro™
NLAB Spiro™ is Nanologica’s technology platform for inhalation. The platform is constituted of biologically degradable nanoporous silica particles that can be loaded with APIs inside the pores of the particles. The particles are spherical, non-aggregating and appears as a free-flowing powder. The aerodynamical properties are tailored for inhalation and the particle size ranges between 2 µm and 5 µm, which means they can reach a desired part of the lung – the smaller the particle, the deeper into the lung it can reach. Once reaching the lung, the API is released giving a treatment effect locally. NLAB Spiro™ can improve solubility and/or the bioavailability of APIs, protect APIs from degradation, provide a controlled release profile, enable local treatment with lowered systemic effects, and enable combination therapies of several APIs, creating new treatment options for lung diseases.